Drugs in induction and treatment of idiopathic inflammatory myopathies - Wikidata - wikimedia - TriplyDB

Drugs in induction and treatment of idiopathic inflammatory myopathies

Drugs in induction and treatment of idiopathic inflammatory myopathies

http://www.wikidata.org/entity/Q35281940

about

Elevated risk of venous thromboembolic events in patients with inflammatory myopathies Current pharmacological treatment of idiopathic inflammatory myopathies.

P2860

Q26746904-7B6A5D45-30D6-49FA-974B-F47BA45B0CE2 Q38680762-CDEB9FB9-F30C-4B86-870E-B10A1C4B8D4E

P2860

Drugs in induction and treatment of idiopathic inflammatory myopathies

http://www.wikidata.org/entity/Q35281940

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Drugs in induction and treatment of idiopathic inflammatory myopathies

@ast

Drugs in induction and treatment of idiopathic inflammatory myopathies

@en

type

label

Drugs in induction and treatment of idiopathic inflammatory myopathies

@ast

Drugs in induction and treatment of idiopathic inflammatory myopathies

@en

prefLabel

Drugs in induction and treatment of idiopathic inflammatory myopathies

@ast

Drugs in induction and treatment of idiopathic inflammatory myopathies

@en

P1433

Q35281940-BB0640F8-C750-4E30-B375-566C7049CACC

P1476

Q35281940-DAD01F1D-AD76-42AA-9A48-44E30BC46DB2

P2093

Q35281940-411CF777-D909-4FA8-A7AE-C00EEE857681

Q35281940-56E04393-47AB-44C6-87F7-4A43A23FA608

Q35281940-82E670EF-7A1E-4D94-8E85-79C345B5FAE9

Q35281940-AAF1D149-A947-4297-AC14-6F82747FD5E1

Q35281940-BE02E0FE-EF09-4086-A16B-4CBD2D65A89D

Q35281940-C83D7B53-344A-4596-83E6-D674A9E66354

Q35281940-E51B5599-D0DC-4842-BD31-65FB20C241CA

Q35281940-FC01192C-409A-4C29-AEA6-A0B016EF9F64

P2860

Q35281940-001A21D3-7568-4A49-B4EB-245DB6FE3C50

Q35281940-04E493B9-C82F-45E5-AA69-7F5AF30AC6EC

Q35281940-1606E1C3-DF72-4E3E-BA64-1BFD9AAD3C06

Q35281940-187A5CA0-70D2-4DE0-868E-81637199CE01

Q35281940-1ECC21BF-9A51-4EA9-8475-C57963B3A63B

Q35281940-36369ADE-31A3-4D8E-9852-91DC0FB0AD0F

Q35281940-3F5407A1-2429-4A44-8076-3C01E894E4F9

Q35281940-4B781566-EEBB-443C-B872-EE1A9D58BF28

Q35281940-6F24A0A0-558E-4945-9A46-6F8169789314

Q35281940-7656D6DB-94DC-443C-B444-1560CEA73BDE

P2888

Q35281940-53407472-1A4D-4262-8D79-DF2E92B8A0BE

P304

Q35281940-928C1D1D-47CD-4FFF-8DDD-6CEECE2EE8F3

P31

Q35281940-FD5CB413-B603-4A3B-A013-97BB03FE1B1B

P356

Q35281940-C64048A2-AE86-4DA0-8E29-8A6D969BCC2C

P433

Q35281940-3531AABB-9A8A-4481-926C-9DC4B161C710

P478

Q35281940-FE3A6CA3-479E-4203-A980-0A3482C60CEB

P50

Q35281940-74EE6213-4D2A-415A-A5D8-8BBDF1BB2626

Q35281940-D0209097-3FF8-4449-9E0C-41472143DD48

Q35281940-E919A730-BBF7-4B7F-917F-F26CA49C44CC

Q35281940-FC1A09FF-9E68-4B31-9B66-2CA7D9623453

P577

Q35281940-156BD3E9-C19D-48FD-A7A5-4A8272F4CC9F

P698

Q35281940-3BD32E7F-4FE5-4D3D-82C7-8CDAE0FBA8AD

P932

Q35281940-3C4067B4-5C69-4F8B-9722-7B411D796413

P356

S13317-014-0065-Z

P1433

Autoimmunity highlights

P1476

Drugs in induction and treatment of idiopathic inflammatory myopathies

@en

P2093

Alessandra Tripoli

http://www.w3.org/2001/XMLSchema#string

Alessia Alunno

http://www.w3.org/2001/XMLSchema#string

Luca Iaccarino

http://www.w3.org/2001/XMLSchema#string

Margherita Zen

http://www.w3.org/2001/XMLSchema#string

Mariele Gatto

http://www.w3.org/2001/XMLSchema#string

Rosaria Talarico

http://www.w3.org/2001/XMLSchema#string

Rossella Neri

http://www.w3.org/2001/XMLSchema#string

Simone Barsotti

http://www.w3.org/2001/XMLSchema#string

P2860

Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

The clinical features, diagnosis and classification of dermatomyositis.

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

Drug-induced myopathies. An overview of the possible mechanisms.

Update on idiopathic inflammatory myopathies.

Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Drugs interfering with mitochondrial disorders.

P2888

s13317-014-0065-z

P304

95-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13317-014-0065-Z

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Elena Bartoloni

P577

2014-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26000161

http://www.w3.org/2001/XMLSchema#string

P932

4386578

http://www.w3.org/2001/XMLSchema#string